{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE298nnn/GSE298436/"]},"type":"primary"},"statusCodeValue":200,"statusCode":"OK"}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Mus musculus"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298436"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Nobiletin targets CHEK1-H3K27ac-CENPM axis and suppresses the malignancy of colorectal cancer","description":"Pharmacological intervention targeting super-enhancer activity represents a promising therapeutic approach to suppress the expression of oncogenes. The challenges remain in unveiling the key factors accounting for the hyperactive super-enhancers in cancers and small molecules for the functional inhibition. In this study, we identified CHEK1 as a critical factor for sustaining the high level H3K27ac enrichment in the super-enhancer regions of oncogenes. Nobiletin was found as an inhibitor of CHEK1. We made these findings in the efforts to decipher the molecular mechanism underlying a modified Traditional Chinese Medicine formula Liujunzi Decoctiom (mLJZD). We experimentally confirmed the anti-cancer function of mLJZD both in vitro and in vivo. Through an interactive analysis of RNA profiling data, we identified oncogenic CENPM as a critical effector gene that is downregulated by mLJZD","dates":{"publication":"2026/05/31"},"accession":"GSE298436","cross_references":{"GSM":["GSM9014259","GSM9014258","GSM9014265","GSM9014264","GSM9014263","GSM9014262","GSM9014261","GSM9014260"],"GPL":["24247"],"GSE":["298436"],"taxon":["Mus musculus"]}}